Dosing chart / Weight & metabolic
Semaglutide vs Retatrutide
Dose, schedule, route and approval status side by side.
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.
| Semaglutide | Retatrutide | |
|---|---|---|
| Status | FDA-approved | Clinical trials |
| Also known as | Ozempic, Wegovy | LY3437943 |
| Typical dose | 0.25 mg rising to 2.4 mg | 1–12 mg |
| How often | Weekly | Weekly |
| Schedule | Once weekly. Start at 0.25 mg and step up every 4 weeks: 0.5, 1, 1.7, then 2.4 mg. | Once weekly in trials, escalated stepwise from a low starting dose. |
| Daily equivalent | ≈ 36–343 mcg/day | ≈ 0.14–1.7 mg/day |
| Route | Subcutaneous | Subcutaneous |
| Duration | Ongoing | Trials ran 48–80 weeks |
| Notes | Wegovy schedule shown. A 7.2 mg weekly dose (Wegovy HD) was approved in March 2026 for adults who have tolerated 2.4 mg for at least 4 weeks. Ozempic for diabetes is maintained at 0.5–2 mg weekly. Brand products are prefilled pens; the calculator applies to vials only. Boxed warning for thyroid C-cell tumors. | Triple agonist (GLP-1, GIP, glucagon) in Phase 3. Not approved anywhere; any product sold now is unregulated. |
This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the Semaglutide and Retatrutide pages.
Advertisement